Biotechnology

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

A novel oral drug for Alzheimer's avoids a key side effect of current therapies, as its 'detangler' platform shows promise for Parkinson's and other diseases.

A Chinese firm's innovative probiotic packaging just won a top design award, solving a key industry problem and signaling a new era for 'Made in China'.

OmniAb reported declining revenue and a wider net loss for 2025, even as it launched its revolutionary OmniUltra platform and its partners' drugs advance.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

The new iPSC-derived sensory neurons offer a reproducible human model, aiming to fix the broken pipeline of pain research and accelerate new analgesics.

A new federal patent office at the University of Utah aims to democratize innovation and solidify the region's growing status as a tech powerhouse.

Backed by JLL Partners, new platform Talica aims to unify the fragmented but vital surface science market for aerospace, pharma, and other high-tech industries.

Biotech firm ImmunoScape partners with a top US cancer center for a novel trial, backed by a strategic investment from actor Leonardo DiCaprio.

A new growth medium aims to standardize stem cell production, addressing key regulatory and scalability challenges in the booming regenerative medicine market.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

A new platform by CG Life seeks to redefine rare disease advocacy, using film and storytelling to keep the spotlight on 300 million patients every day.

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Amid a volatile market, Ligand presents its sustainable growth blueprint, powered by royalties and partnerships, to top investors this March.

A massive $125M investment empowers five international teams to pursue radical ideas, from cancer-proof people to self-destructing tumors.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.